Skip to main content

OrbiMed Advisors LLC's Form 4 filing

Damora Therapeutics, Inc. (DMRA) · filed Jul 27, 2023

Accession no.
0000947871-23-000789
Filed
Jul 27, 2023, 4:28 PM ET
Trade date
Jul 25, 2023
Filing delay
2 days
Rule 10b5-1 plan
Not checked

This filing lists 3 non-derivative transactions. Open-market sales total $114.5K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
OrbiMed Advisors LLCCIK 000105595110% Owner
OrbiMed Israel GP II, L.P.CIK 000168209010% Owner
OrbiMed Advisors Israel II LtdCIK 000168209310% Owner
OrbiMed Capital GP VII LLCCIK 000176064810% Owner
OrbiMed Genesis GP LLCCIK 000180874410% Owner

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Jul 25, 2023Common StockSSaleDisposed−7,800$2.92F1−$22,776162,153Indirect
Jul 25, 2023Common StockSSaleDisposed−4,700$2.92F1−$13,724909,567Indirect
Jul 25, 2023Common StockSSaleDisposed−26,700$2.92F1−$77,9642,258,987Indirect

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

Represents the weighted average sale price of the shares of the Issuer's common stock sold, ranging from a low of $2.81 to a high of $3.12 per share. The Reporting Persons undertake, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price.

Referenced by the price of 3 transactions in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)